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Abstract 
The application of a tandem condensation/cyclisation/[3+2]-cycloaddition/elimination 
reaction gives an sp3-rich tricyclic pyrazoline scaffold with two ethyl esters in a single 
step from a simple linear starting material. The successive hydrolysis and cyclisation 
(with Boc anhydride) of these 3-dimensional architectures, generates unprecedented 
16-membered macrocyclic bisanhydrides (characterised by XRD). Selective 
amidations could then be achieved by ring opening with a primary amine followed by 
HATU-promoted amide coupling to yield an sp3-rich natural product-like library. 
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1. Introduction 
The development of rapid access strategies towards novel 3-dimensional 
heterocyclic scaffolds is of high interest to organic and medicinal chemists alike.1 We 
have pioneered an approach to complex molecular architectures exploiting two-
directional synthesis to make symmetrical polyelectrophilic linear molecules, which 
undergo tandem reactions when reacted with a range of nucleophiles. These 
diastereoselective processes yield polycyclic structures with multiple stereocentres in 
a single reaction pot.2 We have employed this strategy for the syntheses of several 
natural products over the past decade, including anatoxin-a, histrionicotoxin, 
hippodamine, xenovenine and halichlorine.3 More recently, our attention has been 
drawn to the synthesis of natural product-like scaffolds for chemical library 
synthesis.4 Our previous reports on the use of diester 1 as a substrate for tandem 
cyclisations described access to a variety of novel scaffolds, including 
1,2,3,3a,7,8,9,10-octahydrocyclopenta[4,5]pyrazolo[1,5-a]pyridine containing 
structure 2.4 This complex fused heterocyclic core was synthesised via treatment of 
ketodiester 1 with para-toluenesulfonyl hydrazide resulting in a tandem 
condensation/Michael addition/azamethineimine [3+2] cycloaddition reaction 
sequence, followed by an elimination step, to deliver the desired scaffold. In order to 
exploit this useful strategy for the synthesis of derivatives for library synthesis, a 
method for the selective reaction of the pendant ester functionalities needed to be 
devised with the ultimate goal of producing a library of diamides. Herein we report 
our findings on the selective synthesis of this diamide functionalised polycyclic 
scaffold using a unique dimerisation strategy. 
2. Results and discussion 
The high yielding synthesis of diester 1 can be easily performed on large scale 
(>10 g) in three simple steps from 5-bromopent-1-ene (70% overall yield).3b As 
previously reported, the construction of the polycyclic core could be achieved via 
reaction of 1 with para-toluenesulfonyl hydrazide under reflux to provide 
compound 2. In this instance the reaction was carried out for 24 h resulting in a 
separable mixture of diastereomers 2a and 2b in 37% and 15% isolated yields, 
respectively (52% overall yield; Scheme 1). 
 
Scheme 1.  
The synthesis of 3a and 3b derived from 1. Inset—Ortep diagram of 3a, some hydrogen 
atoms are omitted for clarity, thermal ellipsoids shown at 50%. 
Figure options 
It was proposed that the conversion of 1 to 2 initially proceeded via condensation 
with para-toluenesulfonyl hydrazide to produce N-sulfonyl hydrazone A (Fig. 1). 
Nucleophilic attack of the imine nitrogen onto one of the α,β-unsaturated esters, 
followed by proton transfer, then delivered intermediate B. The azomethine imine 
ylide B is ideally set up for an intramolecular [3+2]-dipolar cycloaddition with the 
remaining olefin (Fig. 1). This process sets the remaining stereochemistry of the 
scaffold core structure to produce intermediate C which underwent rapid elimination 
of para-toluenesulfinic acid to produce 2 (Fig. 1). It was presumed that the formation 
of diastereomer 2b occurred post cycloaddition through a retro-Michael elimination of 
the pyrazoline followed by conjugate addition. A similar epimerisation has been 
noted in a related pyrrolidine system.5 Another possible reaction pathway is the initial 
[3+2]-dipolar cycloaddition via an in situ formed diazointermediate (see SI for 
details). 
 Figure 1.  
Plausible mechanism for the formation of 2. 
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With large quantities of the diastereomeric compounds 2a and 2b in hand, the 
selective reaction of a single ester moiety was attempted (reduction, 
transesterification and transamidation) but met with only limited success. Reduction 
with multiple hydride reagents (NaBH4, LiBH4, LiAlH4 and DIBAL) under a variety of 
conditions generally provided only the doubly reduced product or recovered starting 
material. The same trend was observed when attempting to obtain a 
monohydrolysed product. Treatment of 2awith 1 equiv of NaOH(aq) provided a 48% 
yield of the doubly hydrolysed product and the remainder of the material was 
untouched. Due to the apparent lack of selectivity, it was deemed that gaining a 
selective ester functional group interconversion was not possible without substantial 
further investigation. To circumvent this regioselectivity issue, a new strategy was 
devised involving full hydrolysis of 2 to the diacid 3, followed by a selective amidation 
reaction. Double hydrolysis of 2 was achieved with an excess of hydroxide to 
provide 3a and 3b, in 82% and 64% yields, respectively, after a simple trituration 
(Scheme 1). The recrystallisation of 3a and 3b was performed (MeOH; slow 
evaporation) to provide crystals of sufficient quality to allow analysis by X-ray 
crystallography, hence the relative stereochemistry of both 3a and 3b was 
determined unambiguously (Scheme 1, Inset and SI). 
Using 3a as a model substrate, regioselective amidation of one of the carboxylic acid 
functions was probed. Using a variety of coupling reagents (HATU, CDI, T3P, DCC 
and DSC), stoichiometries, reaction conditions and hydrolytic workups were 
assessed but to no avail. The major problems encountered included double 
amidation, lack of selectivity and purification issues. These observations suggested 
that the issues stemmed from the high reactivity of activated esters formed in situ. 
The concurrent production of a non-polar dimeric species derived from the starting 
diacid 3a was noted as an interesting observation during some reactions. It was 
possible to synthesise dimer 4a by treatment of 3a by Boc anhydride (1.05 equiv), 
with a simple trituration providing macrocycle 4a in 83% yield and high purity 
(Scheme 2). This method was also used to produce the diastereomeric 
macrocycle 4b, albeit in a modest yield of 25% (Scheme 2). The structure of 
both 4a and 4b were confirmed by NMR and X-ray crystallographic analysis, 
demonstrating both the relative configuration and the 16-membered macrocyclic 
dianhydride functionality (Fig. 2). 
 
Scheme 2.  
Synthesis of 4a–b and 5a–d (∗—1H NMR yield post reaction work up). 
Figure options 
 
Figure 2.  
Ortep diagrams of 4a (top) and 4b (bottom), hydrogen atoms and solvent molecules 
(CH2Cl2 for 4a) are omitted for clarity, thermal ellipsoids shown at 50%. 
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With 4a and 4b in hand, an attempt to selectively ring open the macrocycle by 
addition of a primary amine (2.5 equiv) was performed. Pleasingly, initial ring 
opening followed by the second addition of an amine to generate two molecules of 
acid-amide product occurred smoothly. Slow addition of the amine to 4 at low 
temperature was necessary to obtain good selectivities for the aliphatic amidation 
(Scheme 2). The use of benzylamine, n-butylamine and 4-aminomethyl 
tetrahydropyran all provided the acid-amides 5a–d in moderate yields after trituration 
from EtOAc/Et2O. Unfortunately no significant regioselectivity was observed when 
using the secondary amines piperidine and dimethylamine. In addition, anilines were 
also found to be poor reactants due to their low nucleophilicity. The reaction 
selectivity favoured amidation of the aliphatic carbonyl, presumably due the higher 
electrophillicity at this position, with only minor quantities of the regioisomer, diamide 
and regenerated diacid observed. 
A structural analysis was performed where the 3JHH coupling constants of the 
methylene-CH2 were cross-correlated to the torsion angles observed in the solid 
state structures (Table 1). Firstly it was noted that the piperidinyl nitrogen was near 
planar in all of the X-ray crystal structures obtained. This demonstrates the level to 
which the nitrogen lone pair is conjugated through to the α,β-unsaturated ester 
functionality. A gauche–transconformation is adopted by the carboxymethylene 
group in all the solid state structures which accounts for the difference in chemical 
shift in the methylene hydrogens (Δδ = 0.50 ppm). It appears that the proximity of 
one of the methylene hydrogens to the imine like nitrogen causes a downfield shift in 
the 1H NMR (Hb and Hc for the major and minor diastereomeric series, 
respectively, Table 1). Surprisingly large 3JHH coupling constants were observed in 
both macrocycles, 11.7 Hz and 13.1 Hz for 4a and 4b, respectively (Table 1). This 
can be explained due to the macrocycle effectively locking the conformation of the 
carboxymethylene group (torsion angles of >170° are noted in the solid state, Table 
1). 
Table 1. 
Selected 1H NMR and X-ray crystallographic data for compounds 2–6 
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Compound δ Ha(ppm) JHa–
Hc(Hz) 
δ Hb(ppm) JHa–
Hb(Hz) 
δ Hc(ppm) Ha–C–C–
Hctorsion 
angle (°) 
Ha–C–C–
Hb torsion 
angle (°) 
2a 3.80 6.1 3.05 7.9 2.65 — — 
3a 3.86 8.0 3.03 5.9 2.66 172.2 70.8 
4a 4.07 11.7 3.22 2.5 2.61 171.0 72.2 
Compound δ Ha(ppm) JHa–
Hc(Hz) 
δ Hb(ppm) JHa–
Hb(Hz) 
δ Hc(ppm) Ha–C–C–
Hctorsion 
angle (°) 
Ha–C–C–
Hb torsion 
angle (°) 
5a–b ave. 3.87 9.4 2.93 4.4 2.43 — — 
6a–h ave. 3.63 9.6 2.90 4.6 2.39 — — 
2b 4.48 9.0 2.62 6.5 2.78 — — 
3b 4.49 7.4 2.60 8.2 2.78 56.4 174.8 
4b 4.76 3.3 2.47 13.1 2.92 55.9 
54.8 
173.5 
172.2 
5c 4.29 6.9 2.55 8.0 2.73 — — 
Table options 
The second amide bond formation was found to proceed in good to quantitative 
yields when HATU was used as the coupling agent. Both 5a and 5b were coupled to 
piperidine, para-bromobenzylamine, n-butylamine and methylamine to provide the 
diamides 6a–h(Table 2). Figure 3 shows the C Log P versus MW for a proposed 
library of 133 members to demonstrate the areas of chemical space accessed by this 
approach ( Fig. 3).6 
Table 2. 
Amidation reactions of 5a and 5b with various amines 
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Entry R R′ R″ Yield (%) Product 
1 Bn Me H 83 6a 
2 nBu H Quant. 6b 
3 (4-BrC6H4)CH2 H Quant. 6c 
4 –CH2(CH2)3CH2– 76 6d 
5 nBu Me H 63 6e 
6 nBu H 88 6f 
7 (4-BrC6H4)CH2 H 98 6g 
8 –CH2(CH2)3CH2– 88 6h 
Table options 
 Figure 3.  
Chart of C Log P versus MW for a library of 133 compounds based on scaffold 6. 
Figure options 
3. Conclusion 
The use of a rapid access route to the interesting 3-dimensional polycyclic 
1,2,3,3a,7,8,9,10-octahydrocyclopenta[4,5]pyrazolo[1,5-a]pyridine scaffold has been 
employed to provide material for use in library synthesis. The double hydrolysis of 
the ethyl esters of 2 followed by a Boc anhydride mediated macrocyclisation was 
used to prepare bisanhydrides 4a and 4b. These novel, highly interesting 
macrocycles have been fully characterised and the X-ray crystal structures 
determined. This is the first report of the synthesis and use of such macrocyclic 
bisanhydrides. The selective amidation to generate compounds 5a and 5b was 
achieved by addition of primary amines into the bisanhydride 4a at low temperature. 
This novel route provided access to the regioselective acid-amides 5 in only 3 steps 
from the cyclised products 2 with no column chromatography necessary. Further 
derivatisation of acid-amides 5a and 5b was achieved using a HATU mediated 
amide coupling to provide access to the desired diamide derivatives (6a–h). 
4. Experimental 
4.1. General experimental details 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a 400 (Bruker® 
DPX400, or AV400) or 300 MHz (Bruker® DPX300) NMR spectrometers in CDCl3 or 
CD3OD at 300 K (unless stated otherwise). For proton NMR, samples were prepared 
using ca. 5–10 mg of compound dissolved in 1.0 mL of deuterated solvent and for 
carbon NMR using ca. 20 mg of compound dissolved in 1.0 mL of deuterated 
solvent. All spectra were referenced to CHCl3 or CHD2OD the residual hydrogen 
solvent peaks for 1H NMR (CHCl3δ = 7.26 ppm, CHD2OD δ = 3.31) and the solvent 
peak for 13C{1H} NMR (CDCl3δ = 77.0 ppm, CD3OD δ = 49.0). NMR Chemical shifts 
(δ) are reported in ppm; coupling constants (J) are reported in Hz; splitting patterns 
are assigned s = singlet, d = doublet, t = triplet, q = quartet, br = broad signal and 
app = the apparent multiplicity. High resolution mass spectrometry (HRMS) data was 
obtained using a Bruker® MicroTOF spectrometer measured using electrospray 
ionization (ESI) in the positive mode. Solvents, unless otherwise stated, were 
purchased in reagent grade or anhydrous quality and used as received. THF was 
distilled from Na/benzophenone immediately prior to use. Reagents were either 
purchased directly from commercial suppliers or prepared according to literature 
procedures. All reactions were carried out in round bottomed flasks and sealed with 
a glass stopper or a rubber septum equipped with an N2balloon and heated in oil 
baths with a thermocouple temperature control. Reactions were monitored using 
aluminium backed silica thin layer chromatography with a fluorescent dye 
(λ = 254 nm) and visualized under UV illumination or staining with basic KMnO4 or 
bromocresol green dips. Flash column chromatography was performed manually on 
silica gel eluting with hexane/ethyl acetate under pressurised air flow. 
4.2. General procedure for the cyclisation of 1 
In a 1 L round bottomed flask, diester 1 (6.0 g, 19.4 mmol, 1.0 equiv) was dissolved 
in toluene (800 mL) and a large stirrer bar was added. To the reaction mixture was 
added para-toluenesulfonyl hydrazide (4.2 g, 22.6 mmol, 1.2 equiv) and the reaction 
setup was equipped with a Dean–Stark apparatus and condenser. The reaction was 
heated at reflux for 15 h then allowed to cool to room temperature prior to filtration 
through a cotton wool plug. The crude reaction mixture was then reduced down in 
vacuo to yield a thick oil which was subjected to purification via silica gel 
chromatography (1:9 through to 2:3—EtOAc/Pet Ether 40–60). The product 
containing fractions were reduced down to yield diastereomers 2a (2.32 g, 7.2 mmol, 
37% yield) and 2b (953 mg, 3.0 mmol, 15% yield) in an overall yield of 52% 
(2a and 2b elute in this order and are easily separable). 
4.2.1. Compound 2a 
A light yellow oil; 1H NMR (CDCl3, 300 MHz) δ = 4.24 (q, J = 7.1, 2H), 4.14 
(qd, J = 7.1, 1.4, 2H), 3.80 (dddd, J = 11.6, 7.9, 6.1, 2.7, 1H), 3.17 (dd, J = 9.2, 4.1, 
1H), 3.05 (dd, J = 16.3, 6.1, 1H), 2.65 (dd, J = 16.3, 7.9, 1H), 2.22 (m, 1H), 1.93 (m, 
1H), 1.86–1.34 (m, 10H), 1.31 (t, J = 7.1, 3H), 1.25 (t, J = 7.1, 3H); 13C NMR (CDCl3, 
75 MHz) δ = 171.7, 163.8, 138.2, 80.2, 60.4, 60.2, 55.5, 53.2, 38.2, 36.1, 33.4, 32.9, 
32.7, 26.5, 21.8, 14.4, 14.1; MS (ESI) m/z = 667.4 (2 M+H+, 100), 345.2 (M+Na+, 31), 
323.2 (M+H+, 61); HRMS = 323.1970 (calcd = 323.1965 C17H27N2O4+). 
4.2.2. Compound 2b 
Yellow oil; 1H NMR (CDCl3, 300 MHz) δ = 4.48 (m, 1H), 4.27 (qd, J = 7.1, 1.1, 2H), 
4.13 (q, J = 7.1, 2H), 3.23 (dd, J = 9.0, 4.8, 1H), 2.78 (dd, J = 15.0, 6.5, 1H), 2.62 
(dd, J = 15.0, 9.0, 1H), 2.12 (m, 1H), 1.97 (m, 1H), 1.88–1.49 (m, 10H), 1.33 
(t, J = 7.1, 3H), 1.24 (t, J = 7.1, 3H); 13C NMR (CDCl3, 75 MHz) δ = 171.0, 163.4, 
138.3, 78.2, 60.6, 60.5, 57.1, 55.1, 40.0, 39.0, 34.4, 32.8, 28.7, 26.3, 16.9, 14.5, 
14.2; MS (ESI) m/z = 667.4 (2 M+H+, 100), 345.2 (M+Na+, 46), 323.2 (M+H+, 26); 
HRMS = 323.1964 (calcd = 323.1965 C17H27N2O4+). 
4.3. Procedure for the hydrolysis of 2a 
In a 50 mL round bottomed flask, compound 2a (1.0 g, 3.1 mmol, 1.0 equiv) was 
dissolved in THF (23 mL) and a large stirrer bar was added. To the reaction mixture 
was added aqueous NaOH solution (1.0 M, 15.5 mL, 15.5 mmol, 5.0 equiv) and the 
reaction setup was stirred vigorously at room temperature for 24 h. To the reaction 
mixture was then added aqueous HCl (0.5 M, 40 mL) and the mixture extracted with 
EtOAc (3 × 80 mL). The organic extracts were then dried (MgSO4), filtered, and 
reduced in vacuo to yield a crude semisolid which was triturated (EtOAc/Pet Ether 
40–60—1:1, 10 mL) with sonication. The suspended solid was then filtered and 
washed (Pet Ether 40–60, 2 mL) to yield the product 3a (675 mg, 2.53 mmol, 82% 
yield). 
4.3.1. Compound 3a 
Colourless crystalline solid; mp = 161–163 °C; 1H NMR (CD3OD, 400 MHz) δ = 3.83 
(dddd, J = 11.7, 7.7, 6.5, 2.8, 1H), 3.14 (dd, J = 9.3, 3.8, 1H), 2.98 (dd, J = 16.3, 7.7, 
1H), 2.59 (dd, J = 16.3, 6.5, 1H), 2.29 (m, 1H), 1.94 (m, 1H), 1.85–1.50 (m, 9H), 1.31 
(m, 1H); 13C NMR (CD3OD, 101 MHz) δ = 175.2, 167.1, 139.3, 82.4, 56.5, 54.8, 39.0, 
37.0, 34.4, 34.2, 34.1, 27.6, 22.9; MS (ESI) m/z = 289.1 (M+Na+, 100), 267.1 (M+H+, 
19); HRMS = 289.1158 (calcd = 289.1159 C13H18N2NaO4+). Crystals of sufficient 
quality to obtain an X-ray crystal structure (CCDC 1039024) were obtained by slow 
evaporation of 3a from a solution of methanol. 
4.4. Procedure for the hydrolysis of 2b 
In a 100 mL round bottomed flask, compound 2b (953 mg, 3.0 mmol, 1.0 equiv) was 
dissolved in THF (50 mL) and a large stirrer bar was added. To the reaction mixture 
was added aqueous NaOH solution (1.0 M, 20.0 mL, 20.0 mmol, 6.8 equiv) and the 
reaction setup was stirred vigorously at room temperature for 24 h. To the reaction 
mixture was then added aqueous HCl (0.5 M, 40 mL) and the mixture extracted with 
EtOAc (3 × 80 mL). The organic extracts were then dried (MgSO4), filtered, and 
reduced down in vacuo to yield a crude semisolid which was triturated (EtOAc/Pet 
Ether 40–60—1:1, 10 mL) with sonication. The suspended solid was then filtered 
and washed (Pet Ether 40–60, 2 mL) to yield the product 3b (504 mg, 1.89 mmol, 
64% yield). 
4.4.1. Compound 3b 
Off white solid (CCDC 1039026); mp = 154–155 °C; 1H NMR (CDCl3, 
300 MHz) δ = 4.49 (m, 1H), 3.23 (dd, J = 9.0, 4.7, 1H), 2.78 (dd, J = 15.0, 8.2, 1H), 
2.60 (dd, J = 15.0, 7.4, 1H), 2.16 (m, 1H), 2.03–1.51 (m, 11H); 13C NMR (CDCl3, 
75 MHz) δ = 176.5, 166.8, 137.4, 79.4, 56.3, 55.4, 40.1, 38.7, 34.7, 32.6, 29.2, 26.3, 
16.9; MS (ESI) m/z = 555.2 (2 M+Na+, 100), 289.1 (M+Na+, 51), 267.1 (M+H+, 29); 
HRMS = 289.1158 (calcd = 289.1154 C13H18N2NaO4+). 
4.5. Procedure for the macrocyclisation of 3a 
In a 50 mL round bottomed flask, compound 3a (1.25 g, 4.69 mmol, 1.0 equiv) was 
dissolved in MeCN/DMF (10:1, 44 mL) along with DMAP (120 mg, 20 mol %) and a 
stirrer bar was added. To the stirred reaction mixture at −5 °C was added a solution 
of di-tert-butyl dicarbonate (1.08 g, 4.9 mmol, 1.05 equiv dissolved in 20 mL of 
MeCN) dropwise over 10 min and the reaction mixture was allowed to warm up to 
room temperature over 18 h with stirring. The reaction mixture was then worked up 
with aqueous HCl (0.05 M, 120 mL) and extracted with CH2Cl2 (3 × 200 mL). The 
organic extracts were then dried (MgSO4), filtered, and reduced down in vacuo to 
yield a crude solid which was triturated (EtOAc/Pet Ether 40–60—3:1, 5 mL) with 
sonication. The suspended solid was then filtered and washed (EtOAc, 2 mL) to yield 
the product 4a (963 mg, 1.94 mmol, 83% yield). 
4.5.1. Compound 4a 
Colourless crystalline solid; mp = 192–194 °C; 1H NMR (CDCl3, 400 MHz) δ = 4.07 
(app tt, J = 11.7, 2.5, 1H), 3.30 (app t, J = 6.1, 1H), 3.22 (dd, J = 17.5, 11.7, 1H), 
2.61 (dd, J = 17.5, 2.5, 1H), 2.32 (m, 1H), 1.99–1.89 (m, 2H), 1.87–1.35 (m, 9H); 13C 
NMR (CDCl3, 101 MHz) δ = 167.2, 159.7, 133.8, 81.1, 53.6, 52.9, 37.0, 36.9, 35.4, 
33.5, 33.4, 25.8, 21.7; MS (ESI) m/z = 519.2 (M+Na+, 100), 497.2 (M+H+, 17), 289 
(C13H18N2O4+Na+, 32), 193.1 (C11H16N2O+H+, 43); HRMS = 519.2240 
(calcd = 519.2214 C26H32N4NaO6+). Crystals of sufficient quality to obtain an X-ray 
crystal structure (CCDC 1039023) were obtained by slow evaporation of 4a from a 
solution of CH2Cl2/EtOAc—2:1. 
4.6. Procedure for the macrocyclisation of 3b 
In a 25 mL round bottomed flask, compound 3b (375 mg, 1.41 mmol, 1.0 equiv) was 
dissolved in MeCN/DMF (10:1, 13.2 mL) along with DMAP (36 mg, 20 mol %) and a 
stirrer bar was added. To the stirred reaction mixture at −15 °C was added a solution 
of di-tert-butyl dicarbonate (324 mg, 1.48 mmol, 1.05 equiv dissolved in 6.0 mL of 
MeCN) dropwise over 10 min and the reaction mixture was allowed to warm up to 
room temperature over 18 h with stirring. The progress of the reaction was monitored 
by TLC (basic KMnO4 stain) which showed that the reaction was not as clean as 
observed in the synthesis of 4a, hence the reaction was allowed to equilibrate for a 
further 72 h. After this time a further quantity of di-tert-butyl dicarbonate (97 mg, 
0.44 mmol, 0.30 equiv dissolved in 2.0 mL of MeCN) was added dropwise over 
10 min at −15 °C and the reaction mixture was then allowed to warm up to room 
temperature over the subsequent 18 h. At this point little difference to the initial 
analysis was observed so the reaction mixture was then worked up with aqueous 
HCl (0.05 M, 100 mL) and extracted with CH2Cl2 (3 × 80 mL) and EtOAc (2 × 50 mL). 
The organic extracts were combined then dried (MgSO4), filtered, and reduced down 
in vacuo to yield a crude solid which purified via silica gel chromatography (1:9 
through to 2:3—EtOAc/Pet Ether 40–60). The product containing fractions were 
reduced down to yield compound 4b (88 mg, 0.18 mmol, 25% yield). 
4.6.1. Compound 4b 
White crystalline solid; mp = 193–195 °C; 1H NMR (CDCl3, 400 MHz) δ = 4.76 
(ddd, J = 13.1, 5.8, 3.3, 1H), 3.29 (dd, J = 8.7, 5.0, 1H), 2.92 (app t, J = 13.1, 1H), 
2.47 (dd, J = 12.9, 3.3, 1H), 2.37 (app dt, J = 12.5, 6.2, 1H), 2.07–1.91 (m, 2H), 
1.84–1.48 (m, 9H); 13C NMR (CDCl3, 101 MHz) δ = 166.7, 159.2, 135.0, 79.8, 57.1, 
55.7, 40.2, 39.6, 36.2, 32.5, 31.2, 26.0, 17.3; MS (ESI) m/z = 519.2 (M+Na+, 100), 
497.2 (M+H+, 18), 289 (C13H18N2O4+Na+, 4), 193.1 (C11H16N2O+H+, 11); 
HRMS = 519.2233 (calcd = 519.2214 C26H32N4NaO6+). Crystals of sufficient quality to 
obtain an X-ray crystal structure (CCDC 1039025) were obtained by slow 
evaporation of 4b from a solution of CH2Cl2:EtOAc—2:1. 
4.7. General procedure for the macrocyclic ring opening of 4a and 4b with an amine 
A round bottomed flask, containing a 20 mM solution of 
macrocycle 4a or 4b (1.0 equiv) in MeCN/DMF—1:1 and a stirrer bar was cooled to 
around -18 °C using a salt/ice bath. To the stirred reaction mixture a 0.2 M solution 
of the primary amine (2.5 equiv) in MeCN/DMF 1:1 was added dropwise over 10 min 
and the reaction mixture was allowed to warm up to room temperature over 18 h with 
stirring. The reaction mixture was then worked up with aqueous HCl (0.05 M) and 
extracted thrice with EtOAc. The organic extracts were then dried (MgSO4), filtered, 
and reduced down in vacuo to yield a crude gummy product which was thoroughly 
dried under high vacuum (ca. 1 mbar). The purified products could then be obtained 
by trituration of the crude product with various solvents and solvent mixtures (e.g., 
Et2O, EtOAc/Pet Ether 40–60—1:1, EtOAc/Et2O—1:1) where the suspended solid 
was then filtered and washed (Et2O) to yield the desired product 5. 
4.7.1. Compound 5a 
The general protocol was performed on 0.40 mmol of 4a which (after trituration with 
EtOAc/Et2O—1:1) provided compound 5a (163 mg, 0.46 mmol, 57% yield) as a white 
solid; mp = 96–98 °C; 1H NMR (CDCl3, 400 MHz) δ = 7.29–7.18 (m, 5H), 6.65 (br 
dd, J = 6.7, 5.0, 1H), 4.55 (dd, J = 14.8, 6.7, 1H), 4.25 (dd, J = 14.8, 5.0, 1H), 3.87 
(dddd, J = 12.1, 9.5, 4.3, 2.7, 1H), 3.16 (dd, J = 9.4, 3.9, 1H), 2.95 (dd, J = 14.0, 9.5, 
1H), 2.45 (dd, J = 14.0, 4.3, 1H), 2.19 (ddd, J = 12.8, 6.1, 3.2, 1H), 1.90 (m, 1H), 
1.82–1.61 (m, 6H), 1.60–1.45 (m, 2H), 1.42–1.26 (m, 2H); 13C NMR (CDCl3, 
101 MHz) δ = 170.1, 166.5, 138.2, 137.2, 128.5, 127.6, 127.3, 81.5, 54.7, 54.5, 43.5, 
40.4, 36.1, 33.7, 33.6, 33.0, 26.6, 21.9; MS (ESI) m/z = 378.2 (M+Na+, 89), 356.2 
(M+H+, 100); HRMS = 356.1979 (calcd = 519.1969 C20H26N3O3+). 
4.7.2. Compound 5b 
The general protocol was performed on 0.40 mmol of 4a which (after trituration with 
Et2O) provided compound 5b (116 mg, 0.36 mmol, 45% yield) as a white solid; 
mp = 182–185 °C; 1H NMR (CDCl3, 400 MHz) δ = 6.32 (br m, 1H), 3.86 
(dddd, J = 12.0, 9.2, 4.5, 2.9, 1H), 3.32 (m, 1H), 3.19 (dd, J = 9.3, 3.9, 1H), 3.10 (m, 
1H), 2.90 (dd, J = 13.9, 9.2, 1H), 2.41 (dd, J = 13.9, 4.5, 1H), 2.24 (m, 1H), 1.94 (m, 
1H), 1.84–1.21 (m, 14H), 0.87 (t, J = 7.2, 3H); 13C NMR (CDCl3, 101 MHz) δ = 171.0, 
166.8, 137.1, 81.5, 54.7, 54.7, 40.5, 39.2, 36.2, 33.8, 33.6, 33.1, 31.5, 26.7, 21.9, 
19.9, 13.7; MS (ESI) m/z = 344.2 (M+Na+, 68), 322.2 (M+H+, 100); 
HRMS = 322.2123 (calcd = 522.2125 C17H28N3O3+). 
4.7.3. Compound 5c 
The general protocol was performed on 96 μmol of 4a which (after trituration with 
Et2O) provided compound 5c (37 mg, 107 μmol, 54% yield) as a white solid; 1H NMR 
(CDCl3, 270 MHz) δ = 6.50 (br m, 1H), 3.97–3.82 (m, 3H), 3.39–3.24 (m, 3H), 3.19 
(dd, J = 9.3, 3.6, 1H), 2.98–2.85 (m, 2H), 2.43 (dd, J = 13.8, 4.1, 1H), 2.24 (m, 1H), 
1. 49 (m, 1H), 1.84–1.17 (m, 15H); 13C NMR (CDCl3, 90 MHz) δ = 171.1, 166.9, 
137.0, 81.5, 67.6, 54.7, 45.2, 40.6, 36.2, 35.3, 33.8, 33.7, 33.1, 30.5, 26.7, 21.9 (16 
out of a possibly 17 resonances observed); MS (ESI) m/z = 386.2 (M+Na+, 100), 
364.2 (M+H+, 84); HRMS = 364.2225 (calcd = 364.2231 C19H30N3O4+). 
4.7.4. Compound 5d 
The general protocol was performed on 0.10 mmol of 4b which (after trituration with 
EtOAc/Et2O—3:1) provided compound 5d (33 mg, 0.09 mmol, 46% yield) as a white 
solid; 1H NMR (CDCl3, 400 MHz) δ = 7.36–7.22 (m, 5H), 6.10 (br m, 1H), 4.48 
(dd, J = 14.6, 5.9, 1H), 4.38 (dd, J = 14.6, 5.5, 1H), 4.29 (m, 1H), 3.23 (dd, J = 8.8, 
4.5, 1H), 2.73 (dd, J = 15.0, 8.0, 1H), 2.55 (dd, J = 15.0, 6.9, 1H), 2.03–1.52 (m, 
11H), 1.39 (m, 1H); 13C NMR (CDCl3, 101 MHz) δ = 170.2, 165.5, 138.5, 138.0, 
128.7, 127.9, 127.5, 79.2, 56.3, 55.6, 43.7, 40.8, 40.4, 34.2, 32.6, 28.7, 26.1, 16.8; 
MS (ESI) m/z = 378.2 (M+Na+, 100), 356.2 (M+H+, 22); HRMS = 356.1971 
(calcd = 519.1969 C20H26N3O3+). 
4.8. General procedure for the coupling of 5a and 5b with an amine 
To a round bottomed flask equipped with a stirrer bar, containing a 100 mM solution 
of carboxylic acid 5a or 5b (1.0 equiv) in DMF, the amine (2.0 equiv) and DIPEA 
(2.0 equiv: note if a hydrochloride salt of the amine was used a larger excess of 
DIPEA was as used as appropriate) was added. The reaction vessel was cooled to 
around −18 °C using a salt/ice bath and a solution of HATU (ca. 0.5 M) was added, 
the reaction mixture was allowed to warm up to room temperature over 18 h with 
stirring. The reaction mixture was then worked up with the addition of aqueous 1 M 
HCl (30 mL) and extracted with EtOAc (100 mL). The organic extract was washed 
sequentially aqueous 1 M HCl (30 mL), saturated NaHCO3(aq) (30 mL) and 20% brine 
(2 × 30 mL). The organic solution was then dried (MgSO4), filtered, and reduced 
down in vacuo and dried under high vacuum (ca. 1 mbar) to yield the desired 
product 6. 
4.8.1. Compound 6a 
The general protocol was performed on 0.11 mmol of 5a which provided 
compound 6a(34 mg, 93 mmol, 83% yield) as a clear gum; 1H NMR (CDCl3, 
300 MHz) δ = 7.33–7.17 (m, 5H), 6.33 (br m, 1H), 6.23 (br m, 1H), 4.50 (dd, J = 14.6, 
6.0, 1H), 4.33 (dd, J = 14.6, 5.1, 1H), 3.65 (dddd, J = 11.8, 9.9, 4.4, 2.8, 1H), 3.18 
(dd, J = 9.7, 4.5, 1H), 2.94 (dd, J = 15.0, 9.9, 1H), 2.81 (d, J = 5.5, 3H), 2.45 
(dd, J = 15.0, 4.4, 1H), 2.06 (ddd, J = 12.2, 6.3, 2.9, 1H), 1.90 (m, 1H), 1.74–1.20 (m, 
10H); 13C NMR (CDCl3, 101 MHz) δ = 170.1, 163.4, 145.9, 138.1, 128.7, 127.7, 
127.5, 80.6, 55.7, 53.7, 49.3, 43.6, 40.4, 35.9, 32.1, 32.0, 27.2, 25.8, 21.6; MS 
(ESI) m/z = 391.2 (M+Na+, 89), 369.2 (M+H+, 100); HRMS = 369.2299 
(calcd = 369.2285 C21H28N4O2+). 
4.8.2. Compound 6b 
The general protocol was performed on 0.11 mmol of 5a which provided 
compound 6b(46 mg, 0.11 mmol, quantitative yield) as a clear gum; 1H NMR (CDCl3, 
300 MHz) δ = 7.33–7.18 (m, 5H), 6.37 (br m, 1H), 6.26 (br m, 1H), 4.49 (dd, J = 14.7, 
6.0, 1H), 4.35 (dd, J = 14.7, 5.2, 1H), 3.64 (dddd, J = 11.8, 9.8, 4.4, 2.8, 1H), 3.25 
(m, 2H), 3.16 (dd, J = 9.8, 4.6, 1H), 2.97 (dd, J = 15.1, 9.8, 1H), 2.43 (dd, J = 15.1, 
4.4, 1H), 2.05 (ddd, J = 12.0, 5.8, 3.4, 1H), 1.90 (m, 1H), 1.76–1.22 (m, 14H), 0.91 
(t, J = 7.3, 3H); 13C NMR (CDCl3, 101 MHz) δ = 171.1, 162.7, 146.1, 138.1, 128.7, 
127.6, 127.5, 80.7, 55.7, 53.7, 43.6, 40.4, 38.9, 35.8, 32.1, 32.0, 32.0, 31.9, 27.2, 
21.6, 20.2, 13.8; MS (ESI) m/z = 433.3 (M+Na+, 99), 411.3 (M+H+, 100); 
HRMS = 411.2773 (calcd = 411.2755 C24H34N4O2+). 
4.8.3. Compound 6c 
The general protocol was performed on 0.11 mmol of 5a which provided 
compound 6c(59 mg, 0.11 mmol, quantitative yield) as a white solid; mp = 168–
170 °C; 1H NMR (CDCl3, 300 MHz) δ = 7.42 (d, J = 8.4, 2H), 7.28–7.23 (m, 3H), 
7.20–7.15 (m, 2H), 7.12 (d, J = 8.4, 2H), 6.57 (br m, 1H), 6.19 (br m, 1H), 4.48 
(dd, J = 15.0, 6.0, 1H), 4.45 (dd, J = 15.0, 6.3, 1H), 4.32 (dd, J = 15.0, 2.8, 1H), 4.30 
(dd, J = 15.0, 1.9, 1H), 3.68 (dddd, J = 12.0, 9.5, 4.7, 2.8, 1H), 3.19 (dd, J = 9.7, 4.5, 
1H), 2.89 (dd, J = 15.0, 9.5, 1H), 2.43 (dd, J = 15.0, 4.7, 1H), 2.09 (m, 1H), 1.94 (m, 
1H), 1.76–1.22 (m, 10H); 13C NMR (CDCl3, 101 MHz) δ = 170.8, 162.9, 144.9, 138.1, 
137.8, 131.7, 129.6, 128.7, 127.6, 127.5, 121.2, 80.8, 55.6, 53.7, 43.5, 42.5, 40.4, 
35.9, 32.3, 32.2 (2×C), 27.2, 21.6; MS (ESI) m/z = 547.2 (MBr81+Na+, 84), 545.2 
(MBr79+Na+, 85), 525.2 (MBr81+H+, 98), 523.2 (MBr79+H+, 100); HRMS = 523.1737 
(calcd = 523.1703 C27H31N4O2Br79+). 
4.8.4. Compound 6d 
The general protocol was performed on 0.05 mmol of 5a which provided 
compound 6d(16.1 mg, 0.038 mmol, 76% yield) as a clear gum; 1H NMR (CDCl3, 
300 MHz) δ = 7.32–7.18 (m, 5H), 6.43 (br m, 1H), 4.48 (dd, J = 14.7, 5.9, 1H), 4.31 
(dd, J = 14.7, 5.2, 1H), 3.69–3.52 (m, 5H), 3.22 (dd, J = 9.6, 5.0, 1H), 2.97 
(dd, J = 14.8, 10.3, 1H), 2.40 (dd, J = 14.8, 4.0, 1H), 2.04 (m, 1H), 1.89 (m, 1H), 
1.76–1.22 (m, 16H); 13C NMR (CDCl3, 101 MHz) δ = 171.3, 162.7, 146.9, 138.1, 
128.7, 127.7, 127.5, 79.0, 58.6, 53.7, 43.6, 40.7, 35.7, 31.9, 31.8, 31.6, 29.7, 27.1, 
24.7, 21.5 (20 out of a possibly 21 resonances observed); MS (ESI) m/z = 445.3 
(M+Na+, 95), 423.3 (M+H+, 100); HRMS = 423.2774 (calcd = 423.2755 C25H35N4O2+). 
4.8.5. Compound 6e 
The general protocol was performed on 75 μmol of 5b which provided 
compound 6e(15.7 mg, 47 μmol, 63% yield) as a clear gum; 1H NMR (CDCl3, 
300 MHz) δ = 6.41 (br m, 1H), 6.04 (br m, 1H), 3.61 (dddd, J = 12.0, 9.5, 4.8, 2.8, 
1H), 3.35–3.10 (m, 2H), 3.20 (dd, J = 9.4, 4.4, 1H), 2.88 (d, J = 5.1, 3H), 2.87 
(dd, J = 14.9, 9.5, 1H), 2.36 (dd, J = 14.9, 4.8, 1H), 2.13 (m, 1H), 1.97 (m, 1H), 1.79–
1.49 (m, 8H), 1.45–1.39 (m, 2H), 1.33–1.21 (m, 4H), 0.88 (t, J = 7.3, 3H); 13C NMR 
(CDCl3, 101 MHz) δ = 171.1, 163.5, 145.6, 80.7, 55.6, 53.8, 40.6, 39.1, 35.9, 32.2, 
32.1, 31.6, 27.3, 25.8, 21.6, 20.0, 13.7; MS (ESI) m/z = 357.2 (M+Na+, 99), 335.2 
(M+H+, 100); HRMS = 335.2447 (calcd = 335.2442 C18H31N4O2+). 
4.8.6. Compound 6f 
The general protocol was performed on 75 μmol of 5b which provided 
compound 6f(25 mg, 67 μmol, 89% yield) as a clear gum; 1H NMR (CDCl3, 
300 MHz) δ = 6.35 (br m, 1H), 6.00 (br m, 1H), 3.61 (dddd, J = 12.0, 9.2, 4.8, 2.7, 
1H), 3.36–3.15 (m, 4H), 3.16 (dd, J = 9.8, 4.6, 5H), 2.90 (dd, J = 15.0, 9.2, 1H), 2.37 
(dd, J = 15.0, 4.8, 1H), 2.13 (m, 1H), 1.98 (m, 1H), 1.83–1.47 (m, 8H), 1.47–1.20 (m, 
6H), 0.94 (t, J = 7.3, 3H), 0.89 (t, J = 7.3, 3H); 13C NMR (CDCl3, 101 MHz) δ = 171.2, 
162.8, 145.6, 80.6, 55.6, 53.8, 40.5, 39.0, 38.8, 35.9, 32.2 (2×C), 32.1, 32.0, 31.6, 
27.2, 21.6, 20.1, 20.0, 13.8, 13.7; MS (ESI) m/z = 399.3 (M+Na+, 89), 377.3 (M+H+, 
100); HRMS = 377.2925 (calcd = 377.2911 C21H37N4O2+). 
4.8.7. Compound 6g 
The general protocol was performed on 75 μmol of 5b which provided 
compound 6g(36 mg, 74 μmol, 98% yield) as a white solid; mp = 61–63 °C; 1H NMR 
(CDCl3, 300 MHz) δ = 7.45 (d, J = 8.4, 2H), 7.20 (d, J = 8.4, 2H), 6.68 (br m, 1H), 
5.86 (br m, 1H), 4.48 (dd, J = 15.0, 6.4, 1H), 4.41 (dd, J = 15.0, 6.0, 1H), 3.65 
(dddd, J = 11.6, 8.6, 5.4, 2.7, 1H), 3.33–3.08 (m, 3H), 2.83 (dd, J = 14.8, 8.6, 1H), 
2.33 (dd, J = 14.8, 5.4, 1H), 2.15 (m, 1H), 1.99 (m, 1H), 1.86–1.50 (m, 8H), 1.48–
1.34 (m, 2H), 1.32–1.17 (m, 4H), 0.86 (t, J = 7.3, 3H) (Note: signals at 4.48 and 4.41 
are heavily roofed); 13C NMR (CDCl3, 101 MHz) δ = 170.9, 163.0, 144.5, 137.8, 
131.7, 129.6, 121.3, 80.8, 55.5, 53.8, 42.5, 40.6, 39.1, 35.9, 32.3 (2×C), 31.6, 27.2, 
21.7, 20.0, 13.7 (Note; 21 out of a possible 22 resonances observed); MS 
(ESI) m/z = 513.2 (MBr81+Na+, 45), 511.2 (MBr79+Na+, 44), 491.2 (MBr81+H+, 98), 
489.2 (MBr79+H+, 100); HRMS = 489.1897 (calcd = 489.1860 C24H34N4O2Br79+). 
4.8.8. Compound 6h 
The general protocol was performed on 75 μmol of 5b which provided 
compound 6h(25.6 mg, 66 μmol, 88% yield) as a white solid; 1H NMR (CDCl3, 
300 MHz) δ = 6.09 (br m, 1H), 3.90–3.50 (br m, 4H), 3.60 (dddd, J = 11.6, 9.8, 4.2, 
2.7, 1H), 3.30–3.16 (m, 3H), 2.85 (dd, J = 14.8, 9.8, 1H), 2.33 (dd, J = 14.8, 4.2, 1H), 
2.12 (m, 1H), 1.98 (m, 1H), 1.81–1.48 (m, 14H), 1.46–1.36 (m, 2H), 1.35–1.21 (m, 
4H), 0.89 (t, J = 7.2, 3H); 13C NMR (CDCl3, 101 MHz) δ = 171.3, 162.8, 146.5, 78.9, 
58.5, 53.7, 40.7, 39.0, 35.7, 32.1, 31.9, 31.6, 29.6, 27.2, 24.7, 21.5, 20.0, 13.7 (18 
out of a possibly 20 resonances observed); MS (ESI) m/z = 411.3 (M+Na+, 100), 
389.3 (M+H+, 97); HRMS = 389.2926 (calcd = 389.2911 C22H37N4O2+). 
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